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Single tablet regimens (STRs) for HIV infection improve patient satisfaction, quality of life, medication adherence, and virological
suppression compared to multitablet regimens (MTRs). This is the first study assessing STR uptake and durability in Australia.
This retrospective audit of all patients receiving an STR (𝑛 = 299) at a large Sydney HIV clinic (January 2012–December 2013)
assessed patient demographics, treatment prior to STR, HIV RNA load and CD4 during MTR and STR dosing, and reasons for
STR switch. 206 patients switched from previous antiretroviral treatment to an STR, of which 88% switched from anMTR. Reasons
for switching included desire to simplify treatment (57%), reduced side effects or toxicity (18%), and cost-saving for the patient.
There was no switching for virological failure. Compared to when on anMTR, patients switching to an STR had significantly lower
HIV RNA counts (𝑝 < 0.001) and significantly higher CD4 counts (𝑝 < 0.001). The discontinuation rate from STR was very low
and all patients who switched to an STR maintained virological suppression throughout the study duration, although the study is
limited by the absence of a control group.
1. Introduction
Advances in the development of antiretroviral agents (ARVs)
for the treatment of HIV have reduced morbidity and
mortality from AIDS [1]. Over the past 2 decades, more
potent, less toxic ARVs have been developed and treatment
regimens of some 20 pills per day are now reduced to once-
daily, single tablet regimens (STRs) incorporating 3 ARVs.
STRs may improve adherence by reducing pill burden and
thus prevent the development of drug-resistance mutations
to individual ARVs in multitablet regimens (MTRs) [2].
There is also an association between ARV pill burden
and risk of hospitalisation. Cohen et al. [3] note that patients
receiving an STR had significantly better rates of adherence
compared to those receiving MTRs, and this translated to
lower rates of hospitalisation. Overall costs were higher with
patients receiving MTRs due to higher pharmacy and inpa-
tient related care costs [3]. A recent Italian study concluded
that the STR not only resulted in better adherence, but
added C4541.00 lower cost-effectiveness ratio per QALY in
comparison with the MTR with a 17% lower cost in favour of
the STR [4].
STRs are generally associated with better adherence and
higher viral suppression [3, 5, 6] and patient-reported out-
comes (i.e., better tolerability and satisfaction with the STR)
are correlatedwith better quality of life [5, 7].That said, adher-
ence to ARVs is not necessarily improved by STRs where
there are differences in access to care, for example, rural ver-
sus urban-based patient populations [8]. STRs also improve
adherence in patients who have other chronic diseases requir-
ing multiple treatments [9, 10]. Indeed, the World Health
Organization (WHO) recommends STRs for the treatment of
hypertension, tuberculosis, and HIV infection [11].
There are 4 STRs approved for use in Australia, that
is (in order of approval), (1) tenofovir/emtricitabine/
efavirenz (Atripla); (2) tenofovir/emtricitabine/rilpivirine
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(Eviplera/Complera); (3) tenofovir/emtricitabine/elvitegra-
vir/cobicistat (Stribild); and (4) dolutegraivir/abacavir/
lamivudine (Triumeq). The STRs “recommended” for initial
therapy in current Australian HIV treatment guidelines
include Atripla and the integrase inhibitor based Stribild
and Triumeq, with Eviplera/Complera listed as “alternative”
regimen in patients with HIV RNA < 100,000 copies/mL and
patients whose CD4 count exceeds 200 cells/𝜇L [12].
To our knowledge, no Australian study hitherto has
compared the efficacy of STRs with MTRs, nor assessed the
reasons patients switch from STRs to MTRs. Atripla and
Eviplera/Complera were the only 2 STRs available when this
study was conducted. Atripla is effective at achieving and
maintaining virological suppression compared with MTRs
[13]. In the STAR study, Eviplera/Complera was statistically
noninferior to Atripla in relation to virological efficacy when
baseline HIV RNA ≥100,000 copies/mL and statistically
superior when baseline HIV RNA <100,000 copies/mL [14].
2. Materials and Methods
Between 1 January 2012 and 31 December 2013, we conducted
a retrospective audit of the medical and ARV dispensing
records for all patients receiving an STR prescribed andman-
aged by a clinic doctor during the said period (patients who
were dispensed medication prescribed by external doctors
were excluded from the analysis). The study was conducted
at Albion Centre, a WHO Collaborating Centre for Capacity
Building and Health Care Worker Training in HIV/AIDS
Care, Treatment and Support, and Australia’s largest public,
multidisciplinary specialist HIV treatment centre, located in
metropolitan Sydney.
Patients completed a brief questionnaire concerning
demographics, current STR, and previous ARV regimen (if
not treatment-naı̈ve). They were asked to specify the main
reason for switching to an STR according to the following
predefined reasons: desire for an STR (convenience), once-
daily dosing, and improved toxicity, previously on a clinical
trial (trial ended), or to state their own reason.
We established the number of Albion Centre patients
receiving STRs including the proportion and reasons com-
menced on an STR as treatment-näıve patients, switched
from an MTR to an STR, switched from an STR to another
STR, and switched from an STR to MTR. We compared the
HIV RNA and CD4 count of those on STRs to those on
MTRs to deduce differences in relative virological efficacy
and immune response.
Patients either initiated an STR as a treatment-näıve
patient or switched from previous treatment to an STR
prior to the study period; that is, all patients were receiving
STRs during the study period and STR switches to an
MTR “discontinuations”were then evaluated to calculate STR
survival (STR switch to an alternative STR was not classified
as a treatment discontinuation for statistical purposes). Mean
HIV RNA and CD4 count were obtained for the duration
of previous therapy with MTR and STR from the medical
record.
Data were analysed using SPSS version 22.0. Regard-
ing statistical analyses, difference in mean HIV RNA
during treatment with MTR versus STR was calculated using
Wilcoxon’s Sign-Rank test; difference in mean CD4 count
during treatment with MTR versus STR was calculated using
a two-tailed paired 𝑡-test; difference in observed proportion
of patient with HIV RNA >20 copies/mL was calculated by
McNemar’s test; and mean estimated STR survival during the
24-month study period was calculated by means of a Kaplan-
Meier survival plot.
The postswitch HIV RNA and CD4 count were taken
as the last available results in the medical record preceding
31 December 2013. No patients were switched for reason of
virological failure. Although the time from the initiation of
STR until the end of study end-date varied for each patient,
this was deemed the best indication of the efficacy of the STR
for the purpose of our analysis. Ethics approval was obtained
from the South Eastern Sydney Local Health District Human
Research Ethics Committee.
3. Results
A total of 299 patients were receiving an STR during the
study period.This represented approximately 25% of all ARV
prescriptions dispensed through our pharmacy at the time.
96% of patients were male and 4% were female. The cohort
mean age was 42 years (range 19–73); 10% (29 patients)
were hepatitis C antibody positive, 6% (18 patients) reported
previous injecting drug use, and 5% (14 patients) were
hepatitis B core antibody positive.
Two-thirds of patients (193) had previously received
ARVs prior to enrolment and one-third (106 patients) were
treatment-näıve. HIV RNA and CD4 counts obtained on the
day of first prescription of an STR, if available, or immediately
preceding the STR initiation, were used to define the “HIV
RNA at switch” and “CD4 at switch” for the purpose of
statistical analyses.
During the study period, 206 patients switched from their
previous ARV regimen to an STR (14 previously treatment-
näıve, 192 previously treated). The details of previous ARV
regimen and switch to an STR are shown in Table 1. Approx-
imately half the patients switched their previous treatment to
Atripla and the other half to Eviplera/Complera. Themajority
(88%, 182 patients) had switched from an MTR, 11% (23
patients) switched from an STR, and 1 patient, who had
received an MTR but stopped treatment prior to the study
period, was commenced on an STR (this patient was counted
as a “switch” for the purpose of the analysis).
3.1. MTR Switch to STR. One hundred and eighty-three
patients received an MTR as previous treatment for a mean
duration of 6.25 years before switching to an STR; 56%
(103 patients) requested the switch in order to simplify their
ARV treatment (i.e., convenience of a single tablet, once-
daily dosing, cost reduction); 17% (32 patients) switched
due to side effects or toxicity (e.g., hypercholesterolaemia,
gastrointestinal symptoms); and 5% (10 patients) switched
for some other reason (namely, immigration to Australia
fromcountrieswith limitedARVaccess, initiation of hepatitis
C treatment, reinitiation of ARV after prolonged interrup-
tion, and previous enrolment in a clinical trial). There was
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Table 1: Disposition of ARV switch to STR.
𝑁
Patients receiving STR 299









From medication trials∗ 4
From prolonged treatment interruption 1
Atripla 95
FromMTR 93
From medication trials∗ 2
∗Patients switched from medication trials categorised as MTR for statistical
analysis.
no reason documented for the MTR switch for 21% of
patients.
Seventy-four percent (136 patients) had HIV RNA <20
copies/mL at the commencement of the STR. Of the 95
patients who switched to Atripla, 70% (67 patients) were
previously taking tenofovir/emtricitabine (Truvada) and
efavirenz as 2 separate ARV tablets. Of the 82 patients who
switched to Eviplera/Complera, 73% (60 patients) were pre-
viously receiving a Truvada backbone with either nevirapine
(14/60 patients), or atazanavir plus ritonavir (21/60 patients),
or lopinavir/ritonavir (Kaletra, 8/60 patients), or raltegravir
(10/60 patients). Remaining patients received a variety of
ARVs.
3.2. STR Switch to STR. Twenty-three patients receiving
Atripla switched to Eviplera/Complera during the study
period. 56% (13 patients) switched due to typical efavirenz
toxicity (neurocognitive symptoms, rash, or lipid elevation)
and 13% (3 patients) switched due to the convenience of
taking their medication with meals. There was no rea-
son for switching STRs documented for 8 patients. No
patients switched fromEviplera/Complera toAtripla. Notably,
10% (30/299 patients) of all switches were from Atripla
due to toxicity. This includes the 23 patients switching to
Eviplera/Complera and 7 other patients who switched from
Atripla to an MTR (discussed below).
3.3. STR Survival. The mean pretreatment HIV RNA as
well as CD4 count for treatment-näıve patients was 122,414
copies/mL and 414 cells/𝜇L, respectively. Mean HIV RNA
and CD4 count were calculated for duration of therapy
with an MTR (i.e., before switch) and an STR (i.e., time
from initiation for treatment-naı̈ve patients or switch for
treatment-experienced patients). Mean HIV RNA and CD4
differed during treatment with MTRs and STRs. Mean HIV
RNA during treatment with MTR was significantly higher
























Figure 1: Durability of STRs over 24 months (𝑛 = 299).
compared to that during treatment with an STR, being 5454
and 1103 RNA copies/mL, respectively (Z = −4.718; 𝑝 <
0.001, Wilcoxon’s Sign-Rank test). (Treatment-näıve patients
were not included in the pre- and postswitch analysis. Only
those switching were analysed to obtain the aforementioned
𝑝 values.)
Mean CD4 count during treatment with MTR was sig-
nificantly lower than that with an STR, mean CD4 being 554
cells/𝜇L and 620 cells/𝜇L, respectively (𝑝 < 0.001, 2-tailed
paired t-test). At the time ofswitch fromanMTR to an STR, or
an STR to an STR, the proportion of patients with HIV RNA
>20 copies/mLwas significantly higherwithMTRs compared
to STRs [69% (38 patients) versus STRs 58% (14 patients),
resp. (𝑝 < 0.001,McNemar’s test)].
The benefits of convenience and improved adherence
with STRs are meaningless if STRs cannot maintain virolog-
ical suppression (durability) which is critical in preventing
HIV disease progression and development of viral resistance.
In terms of survival on an STR, all patients remaining on
an STR maintained virological suppression throughout the
duration of the study (HIV RNA < 20 copies/mL). The
mean estimated survival time on an STR was 23.3 months
calculated by Kaplan-Meier analysis (standard error = 0.204;
95%CI 22.95–23.75), whilst the STR discontinuation rate was
low overall at 3% (10/299) (Figure 1).
Of the 10 patients who switched off an STR to an
MTR during the study period, there were 7 Atripla switches
due to efavirenz toxicity (neurocognitive symptoms, rash,
lipid elevation, and abnormal liver function from hepatitis
C coinfection) and 3 Eviplera/Complera switches due to
declining eGFR, insomnia, rash, or abdominal pain. For
those that switched from an STR to MTR, choices for
regimens included aTruvada backbone plus either raltegravir
or darunavir/ritonavir; or an abacavir/lamivudine (Kivexa/
Epzicom); or zidovudine/lamivudine (Combivir) backbone
plus rilpivirine.
4. Discussion
Atripla and Eviplera/Complera were the only STRs recom-
mended by ARV guidelines and licensed in Australia at the
4 AIDS Research and Treatment
time this study was conducted. To our knowledge, this is the
first study of STR uptake and durability conducted in Aus-
tralia. Most patients (97%) remained on their STR over the 2-
year observation period. Ten patients (3%) ceased their STRs,
due to toxicity or tolerability issues: renal decline secondary
to the tenofovir component of the STRs [15], abnormal blood
lipid profiles, and for several patients complaining of drug-
induced rash or insomnia, all known side effects of efavirenz
[16–18]. Efavirenz was ceased in 3 cases due to viral hepatitis
with subsequent hepatic impairment, which has been shown
to affect plasma levels of efavirenz [19]. Since this study
was undertaken, the integrase inhibitor based STRs Stribild
and Triumeq have come to market and may have been an
appropriate alternative STR for the 10 patients in the study
who switched from Atripla or Eviplera/Complera to an MTR.
STR discontinuation rates vary across studies. Fabbiani
et al. [20] showed a discontinuation rate of ARV therapy
that included efavirenz of 40.6% for MTR versus 17.1% on
STR over 4 years, whereas, in their study of patients taking
Eviplera/Complera, Pinnetti et al. [21] showed a discontin-
uation rate of 13.2% at 12 months. In a cohort analysis,
Rappold et al. [22] described a discontinuation rate <5% over
2 years, which approximates the 1% discontinuation rate for
the patients in our study over the same duration.The reasons
for the low discontinuation rate in our study remain unclear
but may relate to differing follow-up durations and designs of
other studies, relative tolerability of evaluated regimens, the
financial benefit of STRs inAustralia, or ourmultidisciplinary
model of patient care that focuses on maximising ARV
adherence through patient empowerment and expeditious
side effect management.
CD4 counts rise after initiation of ARVs in most patients
who achieve an undetectable HIV RNA load [23]. A lim-
itation of our study is that we cannot determine whether
increases in CD4 in patients switching to STR are due to
the STR per se, increased compliance, or merely natural
immune recovery over time. Another limitation with our
review, apart from its retrospective design, is that we were
unable to compare the 2-year outcomes of patients initiating
an STR with a similar cohort initiating an MTR; that is, there
was no control group in the analysis. Nonetheless, improved
virological suppressionwas clearly demonstrated, with signif-
icantly more patients having undetectable or decreased HIV
RNA loads whilst receiving an STR in our cohort. Finally, our
analysis pooled the treatment-naı̈ve andMTR subjects which
mayhave added bias to the results in terms of relative survival.
The often-chaotic lifestyles associated with recreational
intravenous drug use were initially postulated to be a pre-
dictor of STR usage; however only a relatively low level of
injecting drug use was reported in our cohort. It must be
noted, however, that our records rely on self-reporting by the
patient in questionnaire form on presentation to the clinic.
It is unlikely that the numbers recorded represent a reliable
estimate of intravenous drug use in this community.
5. Conclusion
STRs are an integral option in the treatment of HIV; however,
the initiation of a particular STR, or decision to switch to
one, may depend on factors such as persistence of early
ARV combinations (and patient preference not to change),
improved awareness of cumulative toxicities associated with
specific ARVs, the relative strength of the genetic barrier
to resistance in poorly adherent patients, and other factors,
such as socioeconomic disadvantage, comorbidities, and
interactions with prescribed and illicit drugs.
In this study, Atripla and Eviplera/Complera were asso-
ciated with improved CD4 counts and lower HIV RNA
loads compared to MTRs. Once stabilised on an STR, there
were few discontinuations and virological suppression was
sustained.Most switches from anMTR to an STRwere due to
patient factors, such as pill burden, convenience, tolerability,
and/or cost, whilst therewere very few switches fromone STR
to another due to predicted side effects or dietary limitations.
Our study suggests that once patients are initiated on an STR
they are likely to remain on it over a medium term whilst
maintaining virological suppression. As such, STRs are an
effective option for many patients. The relative benefits of
the newer integrase inhibitor based STRs may further extend
these advantages, but this remains to be tested.
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antiretroviral therapy näıve or switching for simplificationHIV-
infected patients,” BMC Infectious Diseases, vol. 14, article 26,
2014.
[21] C. Pinnetti, S. Di Giambenedetto, F. Maggiolo et al., “Sim-
plification to co-formulated rilpivirine/emtricitabine/tenofovir
in virologically suppressed patients: data from a multicenter
cohort,” Journal of the International AIDS Society, vol. 17, no. 4,
supplement 3, Article ID 19812, 2014.
[22] M. Rappold, A. Rieger, A. Steuer et al., “Treatment modifica-
tion in HIV-Infected individuals starting antiretroviral therapy
between 2011 and 2014,” Journal of the International AIDS
Society, vol. 17, supplement 3, Article ID 19768, 2014.
[23] P. M. Tarwater, J. B. Margolick, J. Jin et al., “Increase and plateau
of CD4 T-cell counts in the 3(1/2) years after initiation of potent
antiretroviral therapy,” Journal of Acquired Immune Deficiency
Syndromes, vol. 27, no. 2, pp. 168–175, 2001.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
